March Biosciences (March Bio) shared encouraging interim clinical data from its ongoing Phase 2 trial of MB-105, a CD5 CAR-T cell therapy for relapsed or refractory T-cell lymphoma, during the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
The Phase 2 safety run-in cohort involved six heavily pre-treated patients who had previously received between two and eight systemic therapies. Interim findings revealed a 100% complete response rate among evaluable patients in the primary efficacy group (≥50% CD5 expression), supported by a favorable safety profile consistent with prior studies.
Key results highlighted robust CAR-T cell expansion, with an average of 75% of total CD3+ T cells detected by day 14, maintaining persistence beyond day 28. Early evidence also indicated a complete clearance of CD5-positive disease in most cases treated.
“These data mark a pivotal moment for March Bio,” said Sarah Hein, Co-Founder and CEO of March Biosciences. “The 100% response rate, combined with manageable safety and durable CAR-T expansion, positions MB-105 as a potentially transformative option for T-cell lymphoma patients.”
Dr. Swami Iyer, Principal Investigator and Professor at The University of Texas MD Anderson Cancer Center, added, “Achieving complete responses in this heavily pre-treated group is an exciting milestone, indicating MB-105 could redefine treatment outcomes in relapsed or refractory T-cell lymphomas.”
March Biosciences is moving ahead with Phase 2 enrollment following approval from the Independent Data Monitoring Committee to progress to Stage 2 of the trial. The company expects to share updated clinical and correlative data at major medical meetings in 2026.
Explore Health-Tech News for the latest advancements in Healthcare Technology & insightful updates from industry experts!
Source: Globenewswire
